Gilead Sciences (GILD) Announces FDA Approval for Biktarvy for Treatment of HIV-1 Infection

February 7, 2018 2:24 PM EST Send to a Friend
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login